FDA takes risk-based approach to PAIs
This article was originally published in The Gold Sheet
FDA is taking a more coordinated risk-based approach to pre-approval inspections that the agency outlined in 1compliance program guidance manual 7346.832, which took effect May 12
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.